JUVELOOK Celebrates 2 Million Vial Milestone

JUVELOOK Celebrates 2 Million Vial Milestone
VAIM announced that its collagen biostimulator JUVELOOK has exceeded 2 million vials in cumulative production as of September 2025.
JUVELOOK is an injectable collagen stimulator that combines PDLLA (Poly D,L-lactide) microparticles with hyaluronic acid (HA). It promotes the natural generation of collagen and elastin, improving skin elasticity and reducing the appearance of wrinkles.
Since its launch in 2019, JUVELOOK has consistently gained attention in both domestic and international markets. To meet growing demand, VAIM expanded its production capacity by completing its third factory in Daejeon in March last year, tripling overall output. With the addition of the second factory in Okcheon and the relocation of its headquarters, VAIM now operates four production facilities, enabling more precise and efficient manufacturing.
A VAIM spokesperson stated, “With the global K-beauty boom, more international visitors are coming to Korea to experience JUVELOOK treatments, and feedback has been overwhelmingly positive. We will continue to enhance consumer satisfaction at home and abroad with differentiated technology and premium-quality products, strengthening our position as a leader in the K-beauty industry.”

Introduction of VAIM
Founded in 2014, VAIM is a global medical aesthetics company that develops human tissue regeneration products and improved pharmaceuticals by utilizing its accumulated technology and know-how in biocompatible and biodegradable polymers. It has developed and patented a PDLLA-based manufacturing technology that reduces the risk of nodule formation compared to other ingredient structures, and in 2019, its subsidiary, VAIM, entered the skin booster market with JUVELOOK, which utilizes this technology. JUVELOOK is a collagen booster that induces the production of ECM (collagen, elastin) to provide direct remodeling effects on the skin such as elasticity and wrinkle improvement, and is divided into JUVELOOK and LENISNA depending on the purpose. After quickly proving its safety and effectiveness since its launch, VAIM currently has product export contracts with 72 countries.